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Clinical Case Report
ABSTRACT
Scleroderma is a rare autoimmune disease characterized by excessive collagen production. The oral manifestations of the 
patient with scleroderma can include microstomia, xerostomia, and changes in the resorption teeth. We report the case of 
a 7-year-old female patient diagnosed with systemic scleroderma where photobiomodulation therapy was used to treat 
xerostomia associated with hyposalivation. She attended a pediatric clinic and presented with dry and rigid facial skin, 
trismus, xerostomia, malocclusion, and difficulty swallowing. Stimulated salivary flow was assessed before, during, and after 
treatment. Photobiomodulation therapy was conducted at four points at the sublingual glands with 660 nm, 100 mW, and 
0.8 J/cm2 to each point; eight points at the parotid glands; and six points at the submandibular glands with 808 nm, 100 
mW, and 0.8 J/cm2 for 8 seconds at each point. After this therapy, an increase in salivary flow, remission of the xerostomia, 
and an improvement in mastication and swallowing were observed. Photobiomodulation therapy was effective in controlling 
xerostomia in this pediatric patient, resulting in increased salivary flow and an improvement in her quality of life. 
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ABBREVIATIONS
LLLT: low-level laser therapy, LSc: localized scleroderma, mW: miliwatts, nm: nanometer, Sc: scleroderma, 
SSc: systemic scleroderma
INTRODUCTION
Scleroderma (Sc) is a rare autoimmune disease 
that causes excessive production of collagen, leading 
to hardening of the skin. It affects the joints, muscles, 
blood vessels, and some internal organs such as 
the lungs and heart. Until now the etiology and 
pathogenesis of Sc are poorly understood, possibly 
due to the rarity of this disease.1
Sc is divided into two types, systemic (SSc) or 
localized (LSc).2 LSc is the most common form of 
Sc; it occurs in about 90% of cases and classically 
presents a benign and self-limiting evolution, and is 
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confined to the skin and/or underlying tissues. SSc is 
the rarest and severe form of Sc, affecting skin and 
some internal organs.3 Sc presents slow, progressive, 
and incapacitating evolution, but it can also occur 
rapidly and lead to death due to the involvement of 
the internal organs.1
According to the literature, Sc can manifest at 
any age, but it is more commonly reported in women 
over 30 years old.1 Herrick et al.4 evaluated the 
annual incidence of SSc in childhood in the United 
Kingdom, and concluded that involvement in children 
under 16 years old is extremely rare.
Oral  manifestat ions may inc lude tongue 
stiffness, microstomia, and hyposalivation followed 
by xerostomia and different degrees of bone and 
teeth resorption.5,6 Non-stimulated salivary flow is 
considered to be hyposalivation with values lower 
than 0.29 mL/min and 1.0 mL/min for stimulated salivary 
flow.7,8 Hyposalivation can lead to poor oral health and 
cause adverse impacts on daily life, such as discomfort 
and pain. Thus, the aim of this article is to report 
successful treatment with photobiomodulation therapy 
(PBMt) for xerostomia followed by hyposalivation in a 
pediatric patient diagnosed with Sc.
CASE REPORT
A 7-year-old girl was attended the emergency 
room and the clinical examination showed dry and 
rigid facial skin, trismus, xerostomia, malocclusion, and 
several carious lesions involving dental elements 54, 
55, 64, 74, 75, 84, and 85 (Figures 1A and 1B).
Dental treatment was started to adjust the oral 
environment; xerostomia and hyposalivation were 
treated with PBMt. Photon Lase III equipment (PL7336, 
DMC, São Carlos, São Paulo, Brazil) was used for the 
treatment and was adjusted to red laser (660 nm—
InGaAlP), power of 100 mW, with an energy density 
of 0.8 J/cm2, 8 seconds per point in the sublingual 
glands. For the parotid and submandibular glands the 
equipment was adjusted for infrared laser (880nm—
AsGaAl) power of 100 mW, with an energy density 
of 0.8 J/cm2, 8 seconds per point. The application 
method was punctually located, with 1 cm distance 
between the application points (8 points in the 
parotid glands, 6 points in the submandibular glands, 
and 4 intra-oral points at sublingual glands), totaling 
six sessions of laser application with a 72-hour interval 
between sessions.
After three sessions of PBMt, lubrication of the oral 
mucosa and remission of the symptomatology were 
reported by the patient. Additionally, initial stimulated 
salivary flow was less than 0.1 mL per minute, and after 
six laser sessions an increase in salivary flow of 1.0 mL 
per minute was observed (Figures 2A and 2B).
D u r i n g  t h e  p e r i o d  o f  t i m e  t h a t  t h e 
photobiomodulation therapy was applied the patient 
did not receive any systemic or topic adjunct treatment.
To date, the patient has had 2 years follow-up 
without change in the clinical aspects obtained with 
the proposed therapy. Furthermore, the patient reports 
an improvement in mastication and swallowing.
DISCUSSION
Figure 1. A – Clinical aspects presented by the patient. It was observed dry skin and microstomia on the extraoral 
exam; B – Several carious lesions and dental crowding in the intraoral exam.
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Frequently, the correct diagnosis of SSc is difficult 
to obtain, because the early stage of the disease is 
very similar to other connective tissue diseases, such 
as systemic lupus erythematosus, polymyositis, and 
rheumatoid arthritis.3 In the present case the patient 
was already diagnosed with Sc. However, dental 
clinics should be aware of the oral manifestations 
of Sc in order to help the diagnosis and treatment 
management.
Few studies in the literature have evaluated 
the effect of PBMt in salivary glands to improve 
sa l i vary  f low however  outcomes have been 
controversial.9-11 Fidelix et al.9 performed a randomized 
clinical trial in xerostomia associated with primary 
Sjögren syndrome. The study group received PBMt 
twice a week for 6 weeks. The laser irradiation 
was adjusted to 808 nm, 100 mW, 4.0 J/cm2 per 
irradiation point. The researchers did not find any 
differences related to xerostomia and salivary flow 
rate. The Biswas et al.10 study evaluated the effect 
of PBMt in the frequency of major water channel 
protein aquaporin 5 (AQP5) in salivary glands during 
hyperglycemia in mice models. The researchers found 
an improvement in salivary function by increasing 
AQP5 membrane distribution in mice that received 
PBMt. Moreover, Lončar et al.11 found a significance 
difference in salivary flow between PBMt groups 
when compared with the control group in an elderly 
population. The researchers concluded that the effects 
of PBMt on salivary glands are not only stimulating 
the salivary flow but also regenerating the quality of 
the saliva.
However, further studies to confirm the potential 
of using PBMt to treat xerostomia and hyposalivation 
symptoms should be carried out. Additionally, the 
precise action mechanism of PBMt in xerostomia 
and hyposalivation is still unknown and poorly 
understood, and should be evaluated in the future. 
There are no precise protocols in the literature 
regarding PBMt for the treatment of hyposalivation 
or xerostomia. Basically, the protocols differ by the 
wavelength used.12
The treatment of xerostomia fol lowed by 
hyposalivation is wide and normally involves the use 
Figure 2. A – Salivary flow stimulated before the PBMt treatment (salivary flow rate <0.1 mL/min); B – After six 
sessions of PBMt there were remission of the symptomatology and an increase in the salivary flow rate to 1.0 mL/min 
were observed.
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of systematic sialagogues, such as pilocarpine and 
cevimeline.13 However, these approaches have many side 
effects. Other options can be the use of intraoral topical 
agents, such as chewing gums, salivary stimulants, 
and salivary substitutes, plus other interventions, 
such as acupuncture and electrostimulation, but with 
questionable results.13 Thus, due to the capability of 
the PBMt in recovering the quality of saliva and being 
easy to apply without side effects, these treatments 
have interest points that must be confirmed with 
further studies.
The present case describes the first case in 
the literature that evaluated the effect of PBMt on 
xerostomia in a pediatric patient diagnosed with SSc. 
Our results strengthen the importance of PBMt as the 
treatment for xerostomia associated with hyposalivation 
in SSc patients, since hyposalivation is a common oral 
manifestation in Sc patients, affecting 52.5% of these 
patients.14 Saliva plays an important role in mastication, 
speech, swallowing, gustatory sensitivity, protection of 
the oral mucosa, and formation of the food bolus. Also, 
it has antibacterial, antifungal, antiviral activities, and 
participates in the mineral balance of dental enamel. 
In this context, deaths from SSc at a ratio of 4% have 
been reported and it is likely that this is associated 
with hyposalivation and its adverse impacts on bad 
nutrition.15 Thus, any effort to treat and recover the 
salivary flow rate and the quality of saliva is very 
significant.16
With this report we have recommended the use of 
PBMt as a possible treatment of xerostomia associated 
with hyposalivation in pediatric SSc patients considering 
its notable success in salivary flow. However, further 
studies in the form of randomized, controlled, clinical 
trials with adequate samples are necessary to confirm 
the findings of this case report, and in vitro studies are 
necessary to evaluate the exact mechanism involved 
in PBMt and salivary glands.
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